{"entity":{"id":"urogen-pharma","kind":"company","name":"UroGen Pharma","aka":["UroGen Pharma Ltd."],"tldr":"UroGen Pharma is a United States-based pharmaceutical company running 3 late-stage cancer trials of UGN-103, UGN-102 and UGN-104 in bladder & urothelial cancer.","summary":"UroGen Pharma, based in Princeton, NJ, the United States, is a pharmaceutical company listed as NASDAQ: URGN. UroGen Pharma develops treatments for urothelial and specialty cancers, including its FDA-approved therapies Zusduri and Jelmyto, based on its proprietary RTGel reverse-thermal hydrogel technology. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (3 in phase 3), testing UGN-103, UGN-102 and UGN-104 in bladder & urothelial cancer. The largest, NCT05243550 (A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer), plans to enrol 240 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.urogen.com"},{"label":"ClinicalTrials.gov: trials led by UroGen Pharma","url":"https://clinicaltrials.gov/search?lead=UroGen%20Pharma%20Ltd."},{"label":"Pipeline page","url":"https://www.urogen.com/pipeline"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["ugn-103","ugn-104"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05243550"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Princeton, NJ","country":"US","companyType":"pharma","website":"https://www.urogen.com","ticker":"NASDAQ: URGN","stage":"public","investors":[],"funding":[]},"route":"/companies/urogen-pharma/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"ugn-103","kind":"drug","name":"UGN-103","route":"/drugs/ugn-103/"},{"id":"ugn-104","kind":"drug","name":"UGN-104","route":"/drugs/ugn-104/"}],"trial":[{"id":"nct05243550","kind":"trial","name":"A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","route":"/trials/nct05243550/"},{"id":"nct06774131","kind":"trial","name":"A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer","route":"/trials/nct06774131/"},{"id":"nct06331299","kind":"trial","name":"A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer","route":"/trials/nct06331299/"}]}}